<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<ep-patent-document id="EP11875217B8W1" file="EP11875217W1B8.xml" lang="en" country="EP" doc-number="2775836" kind="B8" correction-code="W1" date-publ="20181024" status="c" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>BDM Ver 0.1.63 (23 May 2017) -  2999001/0</B007EP></eptags></B000><B100><B110>2775836</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20181024</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>11875217.9</B210><B220><date>20111104</date></B220><B240><B241><date>20140522</date></B241><B242><date>20171116</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B400><B405><date>20181024</date><bnum>201843</bnum></B405><B430><date>20140917</date><bnum>201438</bnum></B430><B450><date>20180912</date><bnum>201837</bnum></B450><B452EP><date>20180405</date></B452EP><B480><date>20181024</date><bnum>201843</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61P  19/06        20060101AFI20180314BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>VERFAHREN ZUR BEHANDLUNG VON GICHTFÄRBUNGEN</B542><B541>en</B541><B542>METHODS FOR TREATING GOUT FLARES</B542><B541>fr</B541><B542>MÉTHODES PERMETTANT DE TRAITER LES ÉRYTHÈMES DE LA GOUTTE</B542></B540><B560><B561><text>US-A1- 2011 268 801</text></B561><B561><text>US-B1- 6 613 802</text></B561><B562><text>BLUHM G B ET AL: "A double blind study comparing halofenate with probenecid in gout", ARTHRITIS &amp; RHEUMATISM, WILEY, US, vol. 18, no. 4, 1 January 1975 (1975-01-01), pages 388-389, XP009183634, ISSN: 0004-3591</text></B562><B562><text>ANONYMOUS: "METABOLEX INITIATES PHASE 2 TRIAL OF ARHALOFENATE Potential Best-in-Class Uricosuric Agent for the Treatment of Gout", INTERNET CITATION, 19 May 2011 (2011-05-19), pages 1-2, XP002682224, Retrieved from the Internet: URL:http://www.metabolex.com/news/may19201 1.html [retrieved on 2012-02-11]</text></B562><B562><text>Schlesinger N: "Management of acute and chronic gouty arthritis: present state-of-the-art. - PubMed - NCBI", , 1 January 2004 (2004-01-01), XP055181670, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/154 81999 [retrieved on 2015-04-08]</text></B562><B565EP><date>20150417</date></B565EP></B560></B500><B700><B720><B721><snm>LAVAN, Brian Edward</snm><adr><str>c/o CymaBay Therapeutics, Inc.
7999 GATEWAY BOULEVARD
SUITE 130</str><city>NEWARK 
CA 94560</city><ctry>US</ctry></adr></B721><B721><snm>SAHA, Gopal Chandra</snm><adr><str>c/o CymaBay Therapeutics, Inc.
7999 GATEWAY BOULEVARD
SUITE 130</str><city>NEWARK
CA 94560</city><ctry>US</ctry></adr></B721><B721><snm>ROBERTS, Brian K.</snm><adr><str>c/o CymaBay Therapeutics, Inc.
7999 GATEWAY BOULEVARD
SUITE 130</str><city>NEWARK
CA 94560</city><ctry>US</ctry></adr></B721><B721><snm>MCWHERTER, Charles A.</snm><adr><str>c/o CymaBay Therapeutics, Inc.
7999 GATEWAY BOULEVARD
SUITE 130</str><city>NEWARK
CA 94560</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>CymaBay Therapeutics, Inc.</snm><iid>101668551</iid><irf>HVH/FP6981153</irf><adr><str>7999 Gateway Boulevard, Suite 130</str><city>Newark, CA 94560</city><ctry>US</ctry></adr></B731><B731><snm>DiaTex, Inc.</snm><iid>101763283</iid><irf>HVH/FP6981153</irf><adr><str>9 Grants Lake Drive</str><city>San Antonio, TX 78248</city><ctry>US</ctry></adr></B731></B730><B740><B741><snm>Wills, Andrew Jonathan</snm><sfx>et al</sfx><iid>101094461</iid><adr><str>Mewburn Ellis LLP 
City Tower 
40 Basinghall Street</str><city>London EC2V 5DE</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>US2011059433</anum></dnum><date>20111104</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2013066353</pnum></dnum><date>20130510</date><bnum>201319</bnum></B871></B870></B800></SDOBI>
</ep-patent-document>
